Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 2 |
| Since 2006 (last 20 years) | 2 |
Descriptor
| Comparative Analysis | 2 |
| Correlation | 2 |
| Drug Therapy | 2 |
| Medical Research | 2 |
| Meta Analysis | 2 |
| Outcomes of Treatment | 2 |
| Bayesian Statistics | 1 |
| Bias | 1 |
| Decision Making | 1 |
| Guidelines | 1 |
| Models | 1 |
| More ▼ | |
Source
| Research Synthesis Methods | 2 |
Author
| Bennetts, Margherita | 2 |
| Boucher, Martin | 2 |
| Dias, Sofia | 2 |
| Pedder, Hugo | 2 |
| Welton, Nicky J. | 2 |
Publication Type
| Journal Articles | 2 |
| Reports - Research | 2 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkPedder, Hugo; Boucher, Martin; Dias, Sofia; Bennetts, Margherita; Welton, Nicky J. – Research Synthesis Methods, 2020
Time-course model-based network meta-analysis (MBNMA) has been proposed as a framework to combine treatment comparisons from a network of randomized controlled trials reporting outcomes at multiple time-points. This can explain heterogeneity/inconsistency that arises by pooling studies with different follow-up times and allow inclusion of studies…
Descriptors: Simulation, Randomized Controlled Trials, Meta Analysis, Comparative Analysis
Pedder, Hugo; Dias, Sofia; Bennetts, Margherita; Boucher, Martin; Welton, Nicky J. – Research Synthesis Methods, 2019
Background: Model-based meta-analysis (MBMA) is increasingly used to inform drug-development decisions by synthesising results from multiple studies to estimate treatment, dose-response, and time-course characteristics. Network meta-analysis (NMA) is used in Health Technology Appraisals for simultaneously comparing effects of multiple treatments,…
Descriptors: Meta Analysis, Guidelines, Drug Therapy, Decision Making
